(INCHEON=NEWSIS) DM Bio Co. Ltd. has opened its Current Good Manufacturing Practice factory in the Incheon Free Economic Zone (IFEZ), in Songdo International City. The company held a factory completion ceremony on May 30, according to the Incheon Free Economic Zone Authority (IFEZA).

A joint venture established in December by Dong-A Socio Holdings and Japan’s Meiji Seika Pharma Co., Ltd., DM Bio aims to promote the global market entry of Korea’s biomedical industry.

Built on a 33,000㎡ site and spanning a total floor area of 21,577㎡, the factory comprises three complexes, including a 3-story factory complex. Each complex has an antibiotic biomedicine production capacity of 2500L, for a total production capacity of 7500L.

The two companies plan to introduce Herceptin biosimilars for breast cancer in Korea and Japan, in 2018. They plan to expand their biomedicine business to the United States and Europe through further developing their site.

“DM Bio’s leap as a global pharmaceutical company will hopefully open up a way to take Korea’s biomedicine industry to the next level,” said IFEZA Director Lee Jong-Cheol. “It is my personal wish that Incheon will become the leading global city in biomedicine, more so than Singapore or the United States.”

kmk@newsis.com

Source Text

Source: Newsis (May. 30, 2014)

** This article was translated from the Korean.